Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Patients With Solid Tumors, including Pancreatic Cancer, or Lymphoma
The purpose of this phase I study is to evaluate the safety of orally administered VMD-928 in adult patients with advanced solid tumors, including pancreatic cancer, or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists.
Study ID: VMO-01C
Trial Phase: Phase I
Trial Sponsor: VM Oncology, LLC
Therapies Used in This Trial: VMD-928